Turnover: 196.6 million EUR (2022)
Country: France
- Biosynex develops, manufactures and markets Medical Devices for Screening, Diagnosis and Prevention.
- The company specializes in in vitro diagnostics, the manufacture of non-contact thermometers, antigenic tests and self-tests
- its rapid growth has been driven by the health crisis
News
Healthcare: Biosynex acquires Theradiag to expand its product range | Healthcare: Biosynex acquires Theradiag to expand its product range. 03/02/2023
- Biosynex has experienced very strong growth with Covid
- Sales rose from €35.2 million in 2019 to €382.5 million in 2021, thanks to sales of contactless thermometers, antigen tests and self-tests.
- Sales are expected to fall back to 196.6 million euros in 2022 (including 76.4 million euros from exports)
- Acquisition of Theradiag (sales of 12.2 million in 2022)
- With this acquisition, the number of employees will rise from 306 to 380
Studies mentioning this company
The in vitro diagnostics market - France
Other companies mentioned:
- Roche Groupe
- Diagast
- Abbott Groupe
- Danaher
- Thermo Fisher Diagnostics
- Sebia
- BioMerieux Groupe
- Diagnostica Stago
- Biosynex
- Diagnostic Medical System DMS
> Besoin de plus d'information sur cette entreprise (SWOT, PESTEL, son marché) ? Demandez à SectorGPT (gratuit)
Sector-GPT est la première IA dédiée aux informations sectorielles.